Evidence map›Paper›PMID 28903348›Full record

ArticleOncotarget2017

Nuclear receptor NR4A1 is a tumor suppressor down-regulated in triple-negative breast cancer.

Hongmei Wu, Jiong Bi, Yan Peng, Lei Huo, Xiaobin Yu, Zhihui Yang, Yunyun Zhou, Li Qin, Yixiang Xu, Lan Liao and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Blocking PPARγ interaction facilitates Nur77 interdiction of fatty acid uptake and suppresses breast cancer progression.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Hongmei Wu *Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Jiong Bi *Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Yan Peng *Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Lei Huo *Department of Pathology, UT MD Anderson Cancer Center, Houston, TX 77030, USA.
Xiaobin YuDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Zhihui YangDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Yunyun ZhouSimmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Li QinDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Yixiang XuDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Lan LiaoDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Yang XieSimmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Orla M ConneelyDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Jos JonkersNetherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, Netherlands.
Jianming XuDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Baylor College of Medicine · USFirst Affiliated Hospital of Sichuan Medical University · CNSouthwestern Medical Center · USThe Netherlands Cancer Institute · NLThe University of Texas MD Anderson Cancer Center · USThe University of Texas Southwestern Medical Center · US

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9M
The Role of SRC-1 in Breast CancerR01CA112403 · NCI · BAYLOR COLLEGE OF MEDICINE · PI XU, JIANMING · 2006 to 2016
$2.9M
NCOA6, A Novel Tumor Suppressor of Endometrial CancerR01CA193455 · NCI · BAYLOR COLLEGE OF MEDICINE · PI XU, JIANMING · 2016 to 2021
$1.9M
DISCOVERY OF SMALL MOLECULAR ACTIVATORS OF NR4A ORPHAN NUCLEAR RECEPTORS R01CA160747 · NCI · BAYLOR COLLEGE OF MEDICINE · PI CONNEELY, ORLA M. · 2012 to 2016
$1.6M
NCI NIH HHS P30 CA125123NCI NIH HHS R01 CA112403NCI NIH HHS R01 CA160747NCI NIH HHS R01 CA193455
6 · The paper itself

Abstract

The nuclear receptor (NR) superfamily contains hormone-inducible transcription factors that regulate many physiological and pathological processes through regulating gene expression. NR4A1 is an NR family member that still does not have an identified endogenous ligand, and its role in cancer is also currently unclear and controversial. In this study, we aimed to define the expression profiles and specific role of NR4A1 in the highly malignant triple-negative breast cancer (TNBC), which still lacks available targeted therapies. Bioinformatic analysis revealed a decrease of NR4A1 mRNA expression in human TNBC samples. Semi-quantitative analysis of NR4A1 protein expression by immunohistochemistry also identified a progressive NR4A1 reduction during the development of mouse basal-like mammary tumors and a significant NR4A1 downregulation in human TNBC samples. Furthermore, the expression levels of NR4A1 in human TNBC were negatively associated with tumor stage, lymph node metastasis and disease recurrence. Moreover, ectopic expression of NR4A1 in MDA-MB-231, a TNBC cell line with little endogenous NR4A1, inhibited the proliferation, viability, migration and invasion of these cells, and these inhibitions were associated with an attenuated JNK1-AP-1-cyclin D1 pathway. NR4A1 expression also largely suppressed the growth and metastasis of these cell-derived tumors in mice. These results demonstrate that NR4A1 is downregulated in TNBC and restoration of NR4A1 expression inhibits TNBC growth and metastasis, suggesting that NR4A1 is a tumor suppressor in TNBC.

Indexed as

gene expressionNR4A1nuclear receptortriple-negative breast cancertumor suppressor

Identifiers

PMID28903348
PMCPMC5589587
OpenAlexW2609524470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.